Skip to main content
Explore URMC
menu

Jeffrey R. Andolina, M.D., M.S.

Contact Information

Phone Numbers

Appointment: (585) 275-2981

Administrative: (585) 275-2981

Office: (585) 275-2981

Fax: (585) 273-1039

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine, Pediatrics

Biography

Dr. Andolina is most interested in the treatment and comprehensive care for children with leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), as well as the care for children with other cancers and blood diseases.

Dr. Andolina is the Director of Pediatric Bone Marrow Transplantation and has experience in treating both Leukemias, as well as non-malignant conditions including aplastic anemia and Immunodeficiencies. He has a particular interest in bone marrow transplant for patients with sickle cell anemia. In addition, Dr. Andolina has an interest in the adolescent and young adult population; he also cares for young adults undergoing bone marrow transplantation.

The University of Rochester is a member of multiple cooperative groups for pediatric cancer and pediatric bone marrow transplantation, including the Children's Oncology Group (COG), the Pediatric Blood and Marrow Tissue Consortium (PBMTC), and the Primary Immune Deficiency Treatment Consortium (PIDTC). Dr. Andolina is an investigator with each of these national groups and is the primary investigator for the PBMTC and PIDTC. He is on both the CML disease committee and also the cellular therapy committee of the COG. Together, we have over 75 clinical trials open and strive to have all front-line treatment studies open for our pediatric and young adult patients.

Please contact Dr. Andolina directly with any patient related or clinical related questions or concerns.

jeffrey_andolina@urmc.rochester.edu

Professional Background

Associate Professor of Pediatrics
Pediatric Hematology/Oncology/Stem Cell Transplantation
Director, Pediatric Bone Marrow Transplantation

Research

Dr. Andolina is interested in improving the outcome for children with cancer through offering enrollment on multi-institutional clinical trials through the Children's Oncology Group (COG) and Pediatric Blood and Marrow Tissue Consortium (PBMTC).

Dr. Andolina has a particular interest in Pediatric Bone Marrow Transplantation; Leukemia; Lymphoma; Neuroblastoma; Hematology, Oncology; Pediatric Hematology Oncology; Pediatric Oncology; Pediatric Cancer.

Dr. Andolina's research interests including improving bone marrow transplantation for children and young adults. He and colleagues have developed a clinical trial using haploidentical donors for bone marrow transplant, for those patients without fully matched sibling or matched unrelated donors. Haploidentical donors are "half matches," and almost all patients will have an available haploidentical donor, as all biological parents and half of full siblings will fall into this category.

Other research interests include evaluating reduced-intensity conditioning regimens for pediatric patients with malignant and non-malignant diseases, especially sickle cell anemia.

Dr. Andolina also performs laboratory research including the study of the gene expression profile of acute lymphoblastic leukemia cells, specifically evaluating gene expression changes which may confer survival advantages post-allogeneic hematopoietic stem cell transplantation.

Please contact Dr. Andolina directly with any patient related or clinical related questions or concerns.

jeffrey_andolina@urmc.rochester.edu

Credentials

Specialties

  • Pediatric Hematology-Oncology - American Board of Pediatrics

Education

2004
MD | University of Virginia School of Medicine

Post-doctoral Training & Residency

07/01/2007 - 06/30/2010
Fellowship in Pediatric Hematology-Oncology at Children's Memorial Hospital

06/21/2005 - 06/30/2007
Residency in Pediatrics at Children's Memorial Hospital

06/21/2004 - 06/20/2005
Internship in Pediatrics at Children's Memorial Hospital

VIEW ALL expand_more

Awards

2021
Faculty Teaching Award for Pediatrics
Sponsor: Medical Student Class of 2022
Location: University of Rochester

2020 - 2020
Faculty Teaching Award for Pediatrics, presented by medical student class of 2021
Sponsor: University of Rochester

2017 - 2018
Faculty Teaching Award for Pediatrics, presented by medical student class of 2019
Sponsor: Pediatric and Medicine-Pediatric Residents Class of 2018
Location: University of Rochester Medical Center

2017 - 2017
Early Career Distinguished Service Award
Sponsor: The Rochester Academy of Medicine
Location: Rochester, New York

2016 - 2016
Young Investigator Award, travel stipend
Sponsor: Pediatric Blood and Marrow Tissue Consortium (PBMTC)

2015 - 2016
Faculty Teaching Award
Sponsor: Pediatric and Medicine-Pediatric Residents Class of 2016
Location: University of Rochester Medical Center

2015 - 2016
Ruth A. Lawrence Academic Faculty Service Award
Location: University of Rochester Medical Center

2015 - 2015
ICare Bronze Star Award
Sponsor: University of Rochester Medical Center
Location: Rochester, New York

2014 - 2015
Faculty Teaching Award for Pediatrics presented by UR Medicine Medical Student Class of 2016
Sponsor: University of Rochester Medical Center
Location: Rochester, New York

2013 - 2014
Alpha Omega Alpha (AOA)
Sponsor: University of Rochester Medical Center
Location: Inducted into AOA by Medical Student Class of 2013

2013 - 2014
Faculty Teaching Award for Pediatrics
Sponsor: Medical Student Class of 2013
Location: University of Rochester Medical Center

2012 - Present
Children's Oncology Group Primary Investigator (PI)
Sponsor: University of Rochester Medical Center
Location: Rochester, New York

2007
A. Todd Davis Physician Award
Location: Children's Memorial Hospital

2007
Resident Teaching Award
Location: Children's Memorial Hospital, Chicago, IL

2005
Resident Teaching Award
Location: Children's Memorial Hospital, Chicago, IL

2004
Gold Humanism in Medicine Honor Society
Location: University of Virginia School of Medicine

VIEW ALL expand_more

Clinical Trials

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma

Lead Researcher: Jeffrey R Andolina

This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab work with or without eflornithine in treating patients with neuroblastoma that has come back (relapsed) or that isn't responding to treatment (refractory). Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as dinutuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Eflornithine blocks the production of chemicals called polyamines that are important in the growth of cancer cells. Giving eflornithine with irinotecan hydrochloride, temozolomide, and dinutuximab, may work better in treating patients with relapsed or refractory neuroblastoma.

View Study Details

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

Lead Researcher: Jeffrey R Andolina

Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation (BMT) has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo this high risk procedure. This study will determine the long term medical condition and daily functioning of participants with CGD after a transplant and if possible, compare these results to participants who do not undergo a transplant.

View Study Details

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Lead Researcher: Jeffrey R Andolina

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

View Study Details

A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)

Lead Researcher: Jeffrey R Andolina

This study is a prospective evaluation of children with Severe Combined Immune Deficiency (SCID) who are treated under a variety of protocols used by participating institutions. In order to determine the patient, recipient and transplant-related variables that are most important in determining outcome, study investigators will uniformly collect pre-, post- and peri-transplant (or other treatment) information on all children enrolled into this study. Children will be divided into three strata: Stratum A: Typical SCID with virtual absence of autologous T cells and poor T cell function Stratum B: Atypical SCID (leaky SCID, Omenn syndrome and reticular dysgenesis with limited T cell diversity or number and reduced function), and Stratum C: ADA deficient SCID and XSCID patients receiving alternative therapy including PEG-ADA ERT or gene therapy. Each Group/Cohort Stratum will be analyzed separately.

View Study Details

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Lead Researcher: Jeffrey R Andolina

This phase III trial studies how well active surveillance, bleomycin, etoposide, carboplatin or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating germ cell tumors.

View Study Details

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma,Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Lead Researcher: Jeffrey R Andolina

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.

View Study Details

Publications

Journal Articles

6/2021
Schenone D, Andolina JR, Rademacher B, Fountaine TJ, Edwards E, Nunez L, Qiu M, Sharma S, Mullen CA. "Gene Expression and Survival of Acute Lymphoblastic Leukemia Cells After Allogeneic Transplant." Anticancer research.. 2021 Jun; 41(6):2781-2793.

5/19/2021
Kaplan FS, Teachey DT, Andolina JR, Siegel DM, Mancilla EE, Hsiao EC, Al Mukaddam M, Rocke DM, Pignolo RJ. "Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva." Bone.. 2021 May 19; 150:116016. Epub 2021 May 19.

5/18/2021
Fries C, Girvin AR, Korones DN, Weintraub L, Fitzpatrick L, Andolina JR. "Myeloablative Carboplatin and Thiotepa With Autologous Stem Cell Rescue for Nonmedulloblastoma High-risk CNS Tumors in Young Children." Journal of pediatric hematology/oncology.. 2021 May 18; Epub 2021 May 18.

Books & Chapters

2019
Chapter Title: White Blood Cells
Book Title: Avery's Neonatology Board Review
Author List: Andolina, JR
Published By: Elsevier 2019

2019
Chapter Title: Transfusion Therapy in Neonates
Book Title: Avery's Neonatology Board Review
Author List: Andolina, JR
Published By: Elsevier 2019

2019
Chapter Title: Solid Tumors and Leukemias
Book Title: Avery's Neonatology Board Review
Author List: Andolina, JR
Published By: Elsevier 2019

VIEW ALL PUBLICATIONS